SCOPUS 정보 검색 플랫폼

The Lancet

Volumn 373, Issue 9665, 2009, Pages 697-698

Improving function: a new treatment era for multiple sclerosis?

(2) Thompson, Alan a Polman, Chris b

a UNIVERSITY COLLEGE LONDON (United Kingdom)

b VU UNIVERSITY MEDICAL CENTER (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE;

ARTICLE; DRUG CONTRAINDICATION; DRUG PACKAGING; HUMAN; MOBILIZATION; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SLOW DRUG RELEASE; WALKING SPEED;

EID: 60649114714 PISSN: 01406736 EISSN: None Source Type: Journal
DOI: 10.1016/S0140-6736(09)60414-1 Document Type: Note

Times cited : (7)

References (8)

1
- 60649090430
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
- on behalf of the Fampridine MS-F203 Investigators
- Goodman A.D., Brown T.R., Krupp L.B., et al., on behalf of the Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373 (2009) 732-738
- (2009) Lancet , vol.373 , pp. 732-738
- Goodman, A.D.¹ Brown, T.R.² Krupp, L.B.³

2
- 0028294639
- 4-aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety
- Polman C.H., Bertelsmann F.W., van Loenen A.C., and Koetsier J.C. 4-aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch Neurol 51 (1994) 292-296
- (1994) Arch Neurol , vol.51 , pp. 292-296
- Polman, C.H.¹ Bertelsmann, F.W.² van Loenen, A.C.³ Koetsier, J.C.⁴

3
- 0035226070
- Aminopyridines for symptomatic treatment in multiple sclerosis
- CD001330.
- Solari A., Uitdehaag B., Giuliani G., Pucci E., and Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 4 (2002) CD001330.
- (2002) Cochrane Database Syst Rev , vol.4
- Solari, A.¹ Uitdehaag, B.² Giuliani, G.³ Pucci, E.⁴ Taus, C.⁵

4
- 52949133688
- Dose comparison trial of sustained-release fampridine in multiple sclerosis
- on behalf of the Fampridine MS-F202 Study Group
- Goodman A.D., Brown T.R., Cohen J.A., et al., on behalf of the Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71 (2008) 1134-1141
- (2008) Neurology , vol.71 , pp. 1134-1141
- Goodman, A.D.¹ Brown, T.R.² Cohen, J.A.³

5
- 55249124510
- Fampridine for MS responders; clinically relevant or hypothesis generating?
- Kryscio R.J. Fampridine for MS responders; clinically relevant or hypothesis generating?. Neurology 71 (2008) 1130-1131
- (2008) Neurology , vol.71 , pp. 1130-1131
- Kryscio, R.J.¹

6
- 0037435521
- Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12)
- Hobart J.C., Riazi A., Lamping D.L., Fitzpatrick R., and Thompson A.J. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Neurology 60 (2003) 31-36
- (2003) Neurology , vol.60 , pp. 31-36
- Hobart, J.C.¹ Riazi, A.² Lamping, D.L.³ Fitzpatrick, R.⁴ Thompson, A.J.⁵

7
- 33746261692
- US Food and Drug Administration (accessed Jan 2, 2008).
- US Food and Drug Administration. Guidance for Industry: patient reported outcome measures. Use in medicinal product development to support labeling claims: draft guidance (2006). http://www.fda.gov/CbER/gdlns/prolbl.pdf (accessed Jan 2, 2008).
- (2006) Guidance for Industry: patient reported outcome measures. Use in medicinal product development to support labeling claims: draft guidance

8
- 58149234344
- 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis
- Burton J.M., Bell C.M., Walker S.E., and O'Connor P.W. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 71 (2008) 1833-1834
- (2008) Neurology , vol.71 , pp. 1833-1834
- Burton, J.M.¹ Bell, C.M.² Walker, S.E.³ O'Connor, P.W.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.